Progressive MS trials: Lessons learned

Serum neurofilament is associated with progression of brain atrophy and disability in early MS

(2017) Jens Kuhle et al.   NEUROLOGY

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis

(2016) Robert J. Fox et al.   Contemporary Clinical Trials

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

(2016) Nicholas D James et al.   LANCET

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis

(2016) Frédéric Sedel et al.   NEUROPHARMACOLOGY

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study

(2016) Ayman Tourbah et al.   Multiple Sclerosis Journal

Pathological mechanisms in progressive multiple sclerosis

(2015) Don H Mahad et al.   LANCET NEUROLOGY

High doses of biotin in chronic progressive multiple sclerosis: A pilot study

(2015) Frédéric Sedel et al.   Multiple Sclerosis and Related Disorders

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

(2014) Jeremy Chataway et al.   LANCET

Simvastatin in patients with progressive multiple sclerosis–Authors' reply

(2014) Jeremy Chataway   LANCET

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Disease Activity Free Status

(2014) Carolyn J. Bevan et al.   JAMA Neurology

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

(2012) P Gergely et al.   BRITISH JOURNAL OF PHARMACOLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis

(2011) Owain W. Howell et al.   BRAIN

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

(2011) M. S. Freedman et al.   NEUROLOGY

A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis

(2010) Roberta Magliozzi et al.   ANNALS OF NEUROLOGY

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

(2009) Volker Brinkmann   BRITISH JOURNAL OF PHARMACOLOGY

A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

(2009) X. Montalban et al.   Multiple Sclerosis Journal

Statins: Mechanisms of neuroprotection

(2009) Peter J. van der Most et al.   PROGRESS IN NEUROBIOLOGY

Disability as an outcome in MS clinical trials

(2008) G. C. Ebers et al.   NEUROLOGY